» Articles » PMID: 39251639

Enhancing Early Parkinson's Disease Detection Through Multimodal Deep Learning and Explainable AI: Insights from the PPMI Database

Overview
Journal Sci Rep
Specialty Science
Date 2024 Sep 9
PMID 39251639
Authors
Affiliations
Soon will be listed here.
Abstract

Parkinson's is the second most common neurodegenerative disease, affecting nearly 8.5M people and steadily increasing. In this research, Multimodal Deep Learning is investigated for the Prodromal stage detection of Parkinson's Disease (PD), combining different 3D architectures with the novel Excitation Network (EN) and supported by Explainable Artificial Intelligence (XAI) techniques. Utilizing data from the Parkinson's Progression Markers Initiative, this study introduces a joint co-learning approach for multimodal fusion, enabling end-to-end training of deep neural networks and facilitating the learning of complementary information from both imaging and clinical modalities. DenseNet with EN outperformed other models, showing a substantial increase in accuracy when supplemented with clinical data. XAI methods, such as Integrated Gradients for ResNet and DenseNet, and Attention Heatmaps for Vision Transformer (ViT), revealed that DenseNet focused on brain regions believed to be critical to prodromal pathophysiology, including the right temporal and left pre-frontal areas. Similarly, ViT highlighted the lateral ventricles associated with cognitive decline, indicating their potential in the Prodromal stage. These findings underscore the potential of these regions as early-stage PD biomarkers and showcase the proposed framework's efficacy in predicting subtypes of PD and aiding in early diagnosis, paving the way for innovative diagnostic tools and precision medicine.

Citing Articles

The two-stage detection-after-segmentation model improves the accuracy of identifying subdiaphragmatic lesions.

Chen C, Hsu S, Hsieh K, Huang K, Lai H Sci Rep. 2024; 14(1):25414.

PMID: 39455821 PMC: 11511953. DOI: 10.1038/s41598-024-76450-6.

References
1.
Cerri S, Mus L, Blandini F . Parkinson's Disease in Women and Men: What's the Difference?. J Parkinsons Dis. 2019; 9(3):501-515. PMC: 6700650. DOI: 10.3233/JPD-191683. View

2.
Chan Y, Bai Y, Hsu J, Huang K, Su T, Li C . Post-traumatic Stress Disorder and Risk of Parkinson Disease: A Nationwide Longitudinal Study. Am J Geriatr Psychiatry. 2017; 25(8):917-923. DOI: 10.1016/j.jagp.2017.03.012. View

3.
Sotgiu I, Rusconi M . Investigating emotions in Parkinson's disease: what we know and what we still don't know. Front Psychol. 2013; 4:336. PMC: 3677123. DOI: 10.3389/fpsyg.2013.00336. View

4.
Sieurin J, Andel R, Tillander A, Valdes E, Pedersen N, Wirdefeldt K . Occupational stress and risk for Parkinson's disease: A nationwide cohort study. Mov Disord. 2018; 33(9):1456-1464. PMC: 6220861. DOI: 10.1002/mds.27439. View

5.
Ho S, Chen I, Chang K, Lin H, Tsai C, Lin C . Equilibrative Nucleoside Transporters-1 Inhibitors Act as Anti-epileptic Agents by Inhibiting Glutamatergic Transmission. Front Neurosci. 2021; 14:610898. PMC: 7773772. DOI: 10.3389/fnins.2020.610898. View